JNCE News and Press, Jounce Therapeutics Inc. From 12/27/22

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (former...

FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potential...

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial res...

Raymond James has downgraded Jounce Therapeutics ( NASDAQ: JNCE ) to outperform from strong buy as full phase 2 data on immunotherapy JTX-2064 now won't be available until H1 2023, instead of the end of this year. The firm also lowered its price target to $3 from $16 (~156...

Jounce Therapeutics, Inc. (JNCE) Q3 2022 Results Earnings Conference Call November 10, 2022, 08:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer and President Hugh Cole - Chief Operating Officer ...

Jounce Therapeutics press release ( NASDAQ: JNCE ): Q3 GAAP EPS of -$0.60 beats by $0.04 . As of September 30, 2022, cash, cash equivalents and investments decreased to $130.3M, compared to $220.2M as of December 31, 2021. The decrease was due to operating expenses inc...

- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 202...

Jounce Therapeutics ( NASDAQ: JNCE ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$0.64 Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. For furthe...

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from ...

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results...